Ignite Creation Date:
2024-05-06 @ 6:40 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05746208
Status:
RECRUITING
Last Update Posted:
2023-12-19
First Post:
2023-02-17
Brief Title:
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
Sponsor:
University of California San Francisco
Organization:
University of California San Francisco
Conditions & Keywords Data
Conditions:
| Name |
|---|
| High Grade Neuroendocrine Carcinoma Any Site |
| Neuroendocrine Tumors |
| Well-Differentiated Neuroendocrine Carcinoma |
Keywords: